Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 137 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ethyl Eicosapentaenoic Acid Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Corneal Nerves Function and Structure

NCT04222660
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Blackmores Omega Daily (4 1g capsules per day)
Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 2, 2026, 2:44 PM EDT
Completed Phase 3 Interventional

TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

NCT00146211
View directory record Official record
Conditions
Huntington Disease
Interventions
Ethyl-EPA (Miraxion™)
Drug
Lead sponsor
Amarin Neuroscience Ltd
Industry
Eligibility
35 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 2, 2026, 2:44 PM EDT
Completed Not applicable Interventional Results available

Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides

NCT00504309
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
4/day of 4g P-OM3 capsules, 4/day of 1g P-OM3 capsules, Corn Oil Placebo, 4 capsules/day for 8 weeks
Drug
Lead sponsor
Penn State University
Other
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 2, 2026, 2:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Role of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Inflammation and Lipids

NCT02670382
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
EPA, DHA, sunflower oil
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
50 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 2, 2026, 2:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL

NCT01696435
View directory record Official record
Conditions
Depression, Depressive Symptoms, Mood
Interventions
vitamin D3, omega-3 fatty acids (fish oil), Fish oil placebo, Vitamin D placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
18,353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 2, 2026, 2:44 PM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

NCT01821833
View directory record Official record
Conditions
Breast Cancer, Ovarian Neoplasm, Pain
Interventions
Omega-3 fatty acid, Placebo, Paclitaxel
Dietary Supplement · Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 2, 2026, 2:44 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Omega-3 Fatty Acids in Sickle Cell Disease

NCT02947100
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
SCD-Omegatex™
Drug
Lead sponsor
Robin E. Miller
Other
Eligibility
8 Years to 25 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 2, 2026, 2:44 PM EDT
Recruiting Not applicable Interventional

OMEGA - Dietary Intervention - COPD Trial

NCT05297279
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
Home delivery Omega-3 rich Food, Dietary Motivational Coaching, Home delivery Food
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 2, 2026, 2:44 PM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression

NCT00361374
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
eicosapentaenoic acid, docosahexaenoic acid, Placebo
Dietary Supplement · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 2, 2026, 2:44 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers Results available

Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)

NCT01782352
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Omega-3 fatty acids (fish oil), Vitamin D3, Vitamin D3 placebo, Fish oil placebo
Drug · Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 2, 2026, 2:44 PM EDT
Completed Phase 2 Interventional

Use of Omega-3 Fatty Acids for Perinatal Depression

NCT00402389
View directory record Official record
Conditions
Depression, Depression, Postpartum
Interventions
Omega-3 Fatty Acids (EPA plus DHA), Supportive psychotherapy, Placebo
Drug · Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 2, 2026, 2:44 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis

NCT02133664
View directory record Official record
Conditions
Multiple Sclerosis, Cognition
Interventions
lipoic acid and omega-3 fatty acids, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 2, 2026, 2:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development of a Metabolic Assessment Tool for Chronic Kidney Disease

NCT01838239
View directory record Official record
Conditions
Immunoglobulin A Nephropathy, Healthy Subjects
Interventions
Fish Oil
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 2, 2026, 2:44 PM EDT
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 2, 2026, 2:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cross-sectional Survey of Omega-3 Fatty Acid Blood Levels

NCT02883764
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
18 Years and older
Enrollment
834 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Parsippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 2, 2026, 2:44 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)

NCT01758081
View directory record Official record
Conditions
Infections, Human Cathelicidin Antimicrobial Peptide (hCAP-18)
Interventions
vitamin D3, omega-3 fatty acids (fish oil), Vitamin D3 placebo, fish oil placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,874 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 2, 2026, 2:44 PM EDT
Recruiting Early Phase 1 Interventional

Differential Thrombogenesis by EPA and DHA Mediated by HDL

NCT06494488
View directory record Official record
Conditions
Lipid Metabolism Disorders, Hypertriglyceridemia
Interventions
EPA, DHA
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 69 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 2, 2026, 2:44 PM EDT
Not listed Phase 2 Interventional

An Open-Label Study of Vascazen in Cardiac Rehab Patients With Deficient Blood Omega-3 Fatty Acid Levels

NCT02052986
View directory record Official record
Conditions
Dyslipidemia
Interventions
VASCAZEN
Other
Lead sponsor
New York Hospital Queens
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Fresh Meadows, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 2, 2026, 2:44 PM EDT
Terminated Phase 4 Interventional

Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels

NCT00578578
View directory record Official record
Conditions
Coronary Artery Disease, Inflammatory Response, Atherosclerosis
Interventions
eicosapentaenoic acid (EPA),
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
19 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Willoughby Hills, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 2, 2026, 2:44 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Effects of Vitamin D and Omega-3 Supplementation on Telomeres in VITAL

NCT04386577
View directory record Official record
Conditions
Aging
Interventions
Vitamin D3 (cholecalciferol), fish oil
Dietary Supplement · Drug
Lead sponsor
Augusta University
Other
Eligibility
50 Years and older
Enrollment
1,054 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 2, 2026, 2:44 PM EDT
Completed Phase 3 Interventional Results available

Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives

NCT02757872
View directory record Official record
Conditions
Hypertension, Kidney Diseases
Interventions
Vitamin D3, Omega-3 Fatty acids, Vitamin D3 placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
50 Years to 99 Years
Enrollment
2,232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 2, 2026, 2:44 PM EDT
Completed Phase 3 Interventional Results available

Age-Related Eye Disease Study 2 (AREDS2)

NCT00345176
View directory record Official record
Conditions
Age-related Macular Degeneration, Cataract
Interventions
Lutein/zeaxanthin, DHA/EPA, Lutein/zeaxanthin and DHA/EPA
Dietary Supplement · Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 85 Years
Enrollment
4,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
91
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 72 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 2, 2026, 2:44 PM EDT
Not listed Phase 2 Interventional

A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)

NCT01202812
View directory record Official record
Conditions
Sickle Cell Disease, HEMOGLOBIN SS, Hemoglobin S Beta-0 Thalassemia, Inflammation, Quality of Life
Interventions
Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA), Placebo Capsules
Dietary Supplement · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
10 Years to 19 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2010 · Synced Oct 2, 2026, 2:44 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Anxiety and Anorexia Nervosa in Adolescents

NCT01933243
View directory record Official record
Conditions
Anxiety, Anorexia Nervosa
Interventions
Fish oil, Placebo pill
Drug
Lead sponsor
Andrea Bonny
Other
Eligibility
12 Years to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 2, 2026, 2:44 PM EDT